Wockhardt Limited – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 77
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: WCEE43EFED3EN
Leaflet:

Download PDF Leaflet

Wockhardt Limited – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Wockhardt Limited - Product Pipeline Review - H2 2011” provides data on the Wockhardt Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Wockhardt Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Wockhardt Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Wockhardt Limited - Brief Wockhardt Limited overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Wockhardt Limited human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Wockhardt Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Wockhardt Limited’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Wockhardt Limited’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Wockhardt Limited in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Wockhardt Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Wockhardt Limited.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Wockhardt Limited and identify potential opportunities in those areas.
Wockhardt Limited Snapshot
Wockhardt Limited Overview
Key Information
Key Facts
Wockhardt Limited – Research and Development Overview
Key Therapeutic Areas
Wockhardt Limited – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Wockhardt Limited – Pipeline Products Glance
Wockhardt Limited Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Wockhardt Limited–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Wockhardt Limited – Drug Profiles
sTU-199
  Product Description
  Mechanism of Action
  R&D Progress
WCK 2349
  Product Description
  Mechanism of Action
  R&D Progress
WCK 4086
  Product Description
  Mechanism of Action
  R&D Progress
WCK 4873
  Product Description
  Mechanism of Action
  R&D Progress
WCK 771
  Product Description
  Mechanism of Action
  R&D Progress
Wockhardt Limited – Pipeline Analysis
Wockhardt Limited – Pipeline Products by Therapeutic Class
Wockhardt Limited - Pipeline Products By Target
Wockhardt Limited – Pipeline Products by Route of Administration
Wockhardt Limited – Pipeline Products by Molecule Type
Wockhardt Limited - Dormant Projects
Wockhardt Limited – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Aug 31, 2006: Wockhardt receives US FDA approval for Cefotaxime Injection; Sixth ANDA approval of 2006
Nov 30, 1999: Morton Grove Pharmaceuticals, Inc. Cleared to Market Its Second Sterile Inhalation Product Albuterol Sulfate Inhalation Solution 0.083%.
Sep 29, 2009: Wockhardt gets final USFDA nod for Timolol Maleate.
Sep 29, 2009: Wockhardt Receives FDA Approval For Tamsulosin Capsules
Sep 29, 2009: Wockhardt Receives FDA Approval For Tamsulosin Capsules For Treatment Of Benign Prostatic Hyperplasia
Sep 28, 2008: Wockhardt gets US FDA nod for Promethazine hydrochloride injection
Apr 28, 2010: Wockhardt Launches Tamsulosin Capsules For Treatment Of Benign Prostatic Hyperplasia In US
Mar 28, 2007: Wockhardt received FDA approval for anti-inflammatory injection, Ketorolac.
Dec 27, 2005: Wockhardt to receive US FDA approval for Zonisamide
Aug 26, 2008: Wockhardt gets tentative approval for Sumatriptan Succinate
Feb 26, 2009: Wockhardt to launch generic version of ulcer drug Ranitidine syrup in the US market
Feb 26, 2009: Wockhardt To Launch Ranitidine Syrup For Treatment Of Ulcers And Hyperacidity In US
Apr 25, 2011: Wockhardt Receives FDA Approval For Generic Version Of Aricept Tablets
Nov 23, 1998: Morton Grove Pharmaceuticals, Inc. Announces Clobetasol Propionate Topical Solution, USP 0.05% Now Cleared for Market.
Jul 23, 2010: Wockhardt Receives FDA Approval For Generic Version Of Toprol XL
Jun 21, 2011: Wockhardt Launches Donepezil In US
Jun 21, 2011: Wockhardt Launches Levofloxacin In US
Jun 21, 2011: Wockhardt Launches Venlafaxine In US
May 21, 2007: Wockhardt Launches Insomnia Drug Zolpidem In The US, Six US FDA Approvals In Two Months
Jan 21, 2011: Wockhardt launches protonix in us
Oct 20, 2010: Wockhardt Receives FDA Approval For Generic Version Of Allegra-D 12 Hour
Jun 20, 2007: Wockhardt to launch Cefprozil, in the US, Eight FDA approval in 4 months
Apr 19, 2011: Wockhardt Receives FDA Approval For Venlafaxine HCl
Apr 19, 2011: Wockhardt receives US FDA approval for generic version of Effexor XR capsules
Nov 18, 2009: Wockhardt launches anti-hypertensive drug Nicardipine injections in USA
Sep 18, 2007: Wockhardt gets US FDA nod to enter the US$ 2.6 billion Norvasc market
Feb 17, 2009: Wockhardt To Launch Generic Version Of Migraine Drug Sumatriptan In US Market
Oct 16, 2008: Wockhardt gets US FDA nod to market Ceftazidime injections
May 16, 2006: Wockhardt receives approval for Ceftriaxone Injection
Apr 16, 2007: Wockhardt gets US FDA nod to market full range of Ceftriaxone antibiotic injection in US
Oct 14, 2009: Wockhardt Receives Final Approval From The US FDA For Risperidone
Nov 13, 2008: Wockhardt launches Midazolam in the US market
Feb 13, 2008: Wockhardt enters the US market with generic version of Zithromax
Jan 13, 2010: Wockhardt Receives FDA Approval For Antibacterial Levofloxacin
Jan 13, 2010: Wockhardt Receives USFDA Approval For Antibacterial Levofloxacin
Feb 12, 2009: Wockhardt To Launch Leveiracetam For Treatment Of Epilepsy In US
Feb 12, 2009: Wockhardt to launch Leveiracetam, a generic version of epilepsy drug in the US market
Mar 11, 2005: Wockhardt announces approval of Famotidine (OTC)
Feb 11, 2009: Wockhardt gets USFDA nod for Sumatriptan Succinate
Feb 11, 2009: Wockhardt To Launch Divalproex ER For Treatment Of Epilepsy In US
Feb 11, 2009: Wockhardt to launch Divalproex ER in the US market.
Jan 11, 1999: Morton Grove Pharmaceuticals, Inc. Announces its First ANDA Approval for 1999 Amantadine Hydrochloride Syrup, USP 50 mg/5 mL Now Cleared For Market
Jul 09, 2007: Wockhardt to launch anti-epileptic injection, Fosphenytoin, in the US, Day 1 launch upon patent expiration
Jan 09, 2008: Wockhardt To Launch Generic Version Of Anti-depressant Zoloft In The US Market
Nov 08, 1999: Morton Grove Pharmaceuticals Inc. cleared to market its first sterile inhalation product Cromolyn Sodium inhalation solution.
Jul 08, 2011: Wockhardt Receives Tentative FDA Approval For Duloxetine Hydrochloride
Nov 06, 2008: Wockhardt receives USFDA approval
Jan 06, 2010: Wockhardt receives US FDA approval for Alzheimer’s drug Memantine
Dec 04, 2008: Wockhardt receives US FDA approval for generic version of Augmentin Suspension
Aug 02, 2005: Wockhardt Receives US FDA Approval For Cefuroxime Axetil
Jun 02, 2006: Wockhardt receives USFDA approval for Clarithromycin
Oct 01, 2009: Wockhardt receives tentative USFDA nod for Alfuzosin tablets
Jul 01, 2011: Wockhardt Receives Tentative FDA Approval For Olopatadine Hydrochloride Eye Drops
Jan 01, 2008: Wockhardt enters billion-dollar anti-allergic Zyrtec market in the US
Financial Deals Landscape
Wockhardt Limited, Deals Summary
Wockhardt Limited, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Sheffield Bio-Science Enters Into Collaboration With Wockhardt
Wockhardt Forms Joint Venture With Representaciones E Investigaciones Medicas
Wockhardt Forms Joint Venture With Pharma Dynamics
Licensing Agreements
Wockhardt Enters Into In-licensing Agreement With DSM Nutritional Products
Wockhardt Enters Into Licensing Agreement With Sinclair Pharma
Wockhardt Enters Into Licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Licensing Agreement With Gnosis
Wockhardt Enters Into An Agreement With SYRIO PHARMA
Wockhardt Enters Into Licensing Agreement With Advanced Biotechnologies
Wockhardt Signs An In-licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Agreement With Life Sciences Investments For Vitix
Debt Offering
Wockhardt Completes Private Placement Of Foreign Currency Convertible Bonds For $110 Million
Asset Transactions
Danone To Acquire Nutrition Business Of Wockhardt
Bristol Laboratories Acquires Luton Plant From Wockhardt
Acquisition
Genopharm Acquires Girex And Mazal From Wockhardt
Wockhardt Completes Sale Of esparma To Mova
Wockhardt Acquires Morton Grove Pharmaceuticals
Wockhardt Acquires Negma Laboratories
Wockhardt Acquires Pinewood Laboratories
Wockhardt Acquires Dumex India From Royal Numico
Wockhardt Acquires esparma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Wockhardt Limited – Pipeline by Therapy Area and Indication, H2 2011
Wockhardt Limited – Pipeline by Stage of Development, H2 2011
Wockhardt Limited – Monotherapy Products in Pipeline, H2 2011
Wockhardt Limited - Phase II, H2 2011
Wockhardt Limited - Phase I, H2 2011
Wockhardt Limited - Pipeline By Therapeutic Class, H2 2011
Wockhardt Limited - Pipeline By Target, H2 2011
Wockhardt Limited – Pipeline By Route of Administration, H2 2011
Wockhardt Limited – Pipeline By Molecule Type, H2 2011
Wockhardt Limited - Dormant Developmental Projects, H2 2011
Wockhardt Limited, Other Locations, H2 2011
Wockhardt Limited, Subsidiaries, H2 2011
Wockhardt Limited, Deals Summary, H2 2011
Sheffield Bio-Science Enters Into Collaboration With Wockhardt
Wockhardt Forms Joint Venture With Representaciones E Investigaciones Medicas
Wockhardt Forms Joint Venture With Pharma Dynamics
Wockhardt Enters Into In-licensing Agreement With DSM Nutritional Products
Wockhardt Enters Into Licensing Agreement With Sinclair Pharma
Wockhardt Enters Into Licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Licensing Agreement With Gnosis
Wockhardt Enters Into An Agreement With SYRIO PHARMA
Wockhardt Enters Into Licensing Agreement With Advanced Biotechnologies
Wockhardt Signs An In-licensing Agreement With Crawford Healthcare
Wockhardt Enters Into Agreement With Life Sciences Investments For Vitix
Wockhardt Completes Private Placement Of Foreign Currency Convertible Bonds For $110 Million
Danone To Acquire Nutrition Business Of Wockhardt
Bristol Laboratories Acquires Luton Plant From Wockhardt
Genopharm Acquires Girex And Mazal From Wockhardt
Wockhardt Completes Sale Of esparma To Mova
Wockhardt Acquires Morton Grove Pharmaceuticals
Wockhardt Acquires Negma Laboratories
Wockhardt Acquires Pinewood Laboratories
Wockhardt Acquires Dumex India From Royal Numico
Wockhardt Acquires esparma

LIST OF FIGURES

Wockhardt Limited – Pipeline by Therapy Area and Indication, H2 2011
Wockhardt Limited – Pipeline by Stage of Development, H2 2011
Wockhardt Limited – Monotherapy Products in Pipeline, H2 2011
Wockhardt Limited – Pipeline By Therapeutic Class, H2 2011
Wockhardt Limited - Pipeline By Target, H2 2011
Wockhardt Limited – Pipeline By Route of Administration, H2 2011

Ask Your Question

Wockhardt Limited – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: